Vasculitis & polymyalgia rheumatica
Exploring relief for Behçet’s disease refractory oral ulcers: a comparison of TNF inhibitors versus apremilast
Authors' conclusion
TNFis and apremilast are both effective for treating BD refractory oral ulcers.
Study context
- Population
- Behçet's disease (BD) patients treated between December 2016 and December 2021 with TNF inhibitors (TNFis) or apremilast for refractory oral ulcersequally allocated
- Participants
- 78 patients
- Exposure
- TNFi vs apremilast for refractory oral ulcers of BD
- Outcome
- Treatment response: absence of oral ulcers
- Follow-up
- 3 and 6 months
Main finding
As reported in the abstract
Oral ulcers
- Both groups showed significant oral ulcer reduction at 3 months
- P < 0.001
- Both groups showed significant oral ulcer reduction at 6 months
- P = 0.01
Observational data: associations, not effects.
Further findings
CS-sparing effect · 3 and 6 months
- Apremilast had a notable CS-sparing effect by 3 months, persisting through 6 months
Genital ulcers
- Both treatments equally effective in reducing genital ulcers
Articular involvement
- TNFis showed greater effectiveness
Original publication
Exploring relief for Behçet’s disease refractory oral ulcers: a comparison of TNF inhibitors versus apremilast. Rheumatology (Oxford). Published 30 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →